StockData
Transcode Therapeutics, Inc. logo

Transcode Therapeutics, Inc. (RNAZ) stock

RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.41+0.06 (+4.44%)

Close on Nov 17, 2026Market cap $1.43MP/E –Yield –

Transcode Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Transcode Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$22.61M. For fiscal 2025 it was -$19.52M. The highest annual figure on record is -$492.97K in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$19.52M–
FY2024Dec 31, 2024-$13.34M–
FY2023Dec 31, 2023-$18.07M–
FY2022Dec 31, 2022-$15.76M–
FY2021Dec 31, 2021-$5.27M–
FY2020Dec 31, 2020-$492.97K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$5.40M–
Q1 FY2026Mar 31, 2026-$4.98M–
Q4 FY2025Dec 31, 2025-$8.14M–
Q3 FY2025Sep 30, 2025-$4.08M–
Q2 FY2025Jun 30, 2025-$4.19M–
Q1 FY2025Mar 31, 2025-$3.10M–
Q4 FY2024Dec 31, 2024-$3.15M–
Q3 FY2024Sep 30, 2024-$3.91M–
Q2 FY2024Jun 30, 2024-$2.34M–
Q1 FY2024Mar 31, 2024-$3.94M–
Q4 FY2023Dec 31, 2023-$5.66M–
Q3 FY2023Sep 30, 2023-$3.51M–
Q2 FY2023Jun 30, 2023-$4.39M–
Q1 FY2023Mar 31, 2023-$4.51M–
Q4 FY2022Dec 31, 2022-$4.02M–
Q3 FY2022Sep 30, 2022-$4.42M–
Q2 FY2022Jun 30, 2022-$3.37M–
Q1 FY2022Mar 31, 2022-$3.95M–
Q4 FY2021Dec 31, 2021-$1.60M–
Q3 FY2021Sep 30, 2021-$3.07M–
Q2 FY2021Jun 30, 2021-$76.00K–
Q1 FY2021Mar 31, 2021-$522.15K–
Q4 FY2020Dec 31, 2020-$255.49K–
Q3 FY2020Sep 30, 2020-$130.84K–

More Transcode Therapeutics figures

See a number that looks wrong?